Will J&J's Q2 Results Reflect End of MedTech Issues & Higher Sales?
In the MedTech segment, newly acquired cardiovascular businesses, Abiomed and Shockwave, as well as continued uptake of its new products, are likely to have driven growth in the second quarter. However, sales in J&J's MedTech business continue to face headwinds in the Asia Pacific, particularly in China. Sales in China are being hurt by the impact of the volume-based procurement (VBP) program and the anticorruption campaign. VBP is a government-driven cost-containment effort in China. J&J does not expect any improvement in its business in the Asia Pacific region, specifically in China, in 2025. JNJ expects continued impacts from VBP issues in China in 2025 as the program expands across provinces and products.
Competitive pressure is also expected to continue to hurt growth in some MedTech businesses, such as PFA ablation catheters in U.S. electrophysiology. In the first quarter, MedTech sales were hurt by several one-time events, mainly impacting orthopedics. This one-time impact is not likely to have hurt sales in the second quarter.
Nonetheless, sales are expected to be higher in the second half of 2025 than in the first half as the business moves past tougher first-quarter comps and new products gain momentum throughout 2025. However, tariff-related costs are expected to hurt profits in the MedTech segment
J&J's Key Competitors in the Medical Devices Market
J&J's MedTech unit faces strong competition from several major players in the medical device industry like Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX.
While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a global leader in medical technology, specializing in innovative solutions across surgical, neurotechnology, orthopedics and spine care. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical device products across cardiovascular, diagnostics, and diabetes care.
JNJ's Price Performance, Valuation and Estimates
J&J's shares have outperformed the industry year to date. The stock has risen 9.7% in the year-to-date period compared with a 0.6% increase of the industry.
Image Source: Zacks Investment Research
From a valuation standpoint, J&J is reasonably priced. Going by the price/earnings ratio, the company's shares currently trade at 14.43 forward earnings, lower than 14.99 for the industry. The stock is also trading below its five-year mean of 15.73.
The Zacks Consensus Estimate for 2025 earnings has risen from $10.60 per share to $10.62 per share for 2025 and from $10.98 per share to $11.00 per share over the past 30 days.
J&J has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.
Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Boston Scientific Corporation (BSX): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
Medtronic PLC (MDT): Free Stock Analysis Report
Stryker Corporation (SYK): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
an hour ago
- CTV News
Estee Lauder forecasts annual profit below estimates as tariffs hit
Estee Lauder said it expects a hit of about US$100 million to its 2026 profit from tariff-related headwinds. Estee Lauder forecast annual profit below Wall Street estimates on Wednesday, as the cosmetics giant grapples with persistent weakness in the U.S. and China markets and tariff uncertainty, sending its shares down about nine per cent in premarket trading. The company also said it expects a hit of about US$100 million to its 2026 profit from tariff-related headwinds. U.S. President Donald Trump and his administration's unpredictable trade policies have strained consumers' wallets as well as put an operational strain on businesses, forcing companies to find ways to counter tariff impact while devising strategies to reignite growth. Estee's organic net sales for the fourth quarter fell 13 per cent, compared with an eight per cent rise a year ago, primarily hurt by weakness in the skincare and makeup segments. To revive sales, Estee Lauder has been accelerating new launches in categories including skincare, introducing new luxury price tiers, increasing investments and implementing cost-savings measures, under new CEO Stephane de La Faverie, who took up the top job earlier this year. The MAC lipstick maker has previously said it expects to take restructuring charges between $1.2 billion and $1.6 billion, before taxes in 2026. The company expects full-year adjusted earnings per share to be in the range of $1.90 to $2.10, compared with analysts' estimates of $2.21, according to data compiled by LSEG. (Reporting by Anuja Bharat Mistry and Anshi Sancheti in Bengaluru; Editing by Shinjini Ganguli)
National Post
3 hours ago
- National Post
Buyback and Burn of $MBG Unveiled as MultiBank Group Posts $209M H1 Revenue
HONG KONG — MultiBank Group, the world's largest financial derivatives institution, has announced a strategic buyback and burn program for its $MBG Utility Token. Backed by strong H1 2025 results, with $209 million in revenue (up 20% year-on-year) and $170 million in profit, the measure is designed to enhance scarcity and drive long-term value for $MBG token holders. Article content Article content MultiBank Group announced a strategic buyback and burn program for its $MBG Utility Token. Backed by H1 2025 results, $209 million in revenue and $170 million in profit, this is designed to enhance scarcity and drive long-term value for $MBG token holders. Article content Since its debut on July 22 across MEXC, and Uniswap, $MBG has surged to seven times its listing price, quickly becoming one of the most closely followed tokens globally. Article content Under the program, $MBG will be repurchased from the open market and permanently removed from circulation. The framework projects up to $58.2 million in buybacks within the first year and a cumulative $440 million over the initial five years. The Group describes the initiative as both a celebration of its H1 results and a gesture of gratitude to its worldwide client base. Article content 'This is our way of thanking our customers and community for their trust,' said Naser Taher, Founder and Chairman of MultiBank Group. 'We've established a solid foundation in traditional finance, and the rapid adoption of $MBG proves we're equally ready to lead in digital assets. The token burn program is just the beginning, and we have more major announcements on the horizon.' Article content The $MBG token powers MultiBank's four-pillar ecosystem: Article content MultiBank TradFi: The Group's traditional CFD powerhouse, which generated $362 million in revenue last year, allows traders to use $MBG for reduced fees and enhanced platform features. MEX Exchange (Institutional ECN): This is a $23.7 billion institutional-grade hybrid FX and crypto ECN for emerging markets. $MBG automates settlement, reduces counterparty risk, and enables smart contract-based margin and delivery versus payment (DvP). (crypto exchange): Regulated across multiple jurisdictions, including the UAE and Australia, the platform offers both spot and leveraged trading. $MBG unlocks reduced costs along with additional utilities such as launchpad access, staking, and token participation opportunities. RWA: Built on Mavryk's layer-1 blockchain, this division stems from the world's largest real-world asset (RWA) tokenization initiative to date, a $3 billion real estate deal with MAG Lifestyle Development. $MBG holders receive fee discounts and early entry to projects. Article content Together, these four pillars are fueling MultiBank's expansion, momentum that is also reflected in the Group's growing community of more than 396,000 members on Telegram and over 280,000 followers across its X channels. With more than two million clients, 17+ financial licenses across five continents, and an unblemished compliance record since 2005, MultiBank Group is accelerating its blockchain and DeFi infrastructure to deliver more value-driven initiatives in the months ahead. Article content Article content ABOUT MULTIBANK GROUP Article content MultiBank Group, Article content established in California, USA in 2005, is a global leader in financial derivatives. With over 2 million clients in 100+ countries and a daily trading volume exceeding $35 billion, it offers a broad range of brokerage and asset management services. Renowned for innovative trading solutions, robust regulatory compliance, and exceptional customer service, the Group is regulated by 17+ top-tier financial authorities across five continents. Its award-winning platforms provide up to 500:1 leverage across Forex, Metals, Shares, Commodities, Indices, and Cryptocurrencies. MultiBank Group has received over 80 international awards for trading excellence and regulatory compliance. Article content Article content
National Post
4 hours ago
- National Post
Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
Article content Improving Access for U.S. Investors and Supporting Share Price Appreciation for Canadian MedTech Innovator Article content MISSISSAUGA, Ontario — Covalon Technologies Ltd. (the 'Company' or 'Covalon') (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through The Depository Trust Company ('DTC'). Article content DTC eligibility simplifies the trading process for Covalon shares on the U.S. OTCQX Market under the symbol CVALF by eliminating manual delays and higher transaction costs often associated with cross-border securities. Article content Most United States-based brokerage firms do not allow their customers to trade shares unless they are DTC eligible. This accomplishment will enable Covalon to generate increased U.S. interest, which will enhance liquidity and improve Covalon's positioning in the United States, where companies with Covalon's financial performance trade at much higher market values. Article content ' This is a major milestone for Covalon as we expand our visibility and access to a broader investor base, ' said Brent Ashton, CEO of Covalon. ' Receiving DTC eligibility significantly streamlines the investment process for U.S. shareholders and demonstrates the commitment to growing our presence in U.S. capital markets, where we have received very positive feedback from investors.' In addition, in the Company's May 15, 2025 press release, Covalon announced the promotion of Kim Crooks appointment to Covalon's Board of Directors, and the awarding of 150,000 common share stock options, both of which were subject to the approval of the TSX Venture Exchange. Article content The Options were granted pursuant to the Company's Omnibus Long-Term Incentive Plan on May 30, 2025, and are subject to the terms of the applicable grant agreement, the requirements of the TSX Venture Exchange, and shareholder approval at the Company's next Annual General Meeting, scheduled in early 2026. Article content The Options were granted at an exercise price of $2.50 per share, effective May 30, 2025. The options vest 34% on the first anniversary of the grant date, 33% on the second anniversary, and the remaining 33% on the third anniversary. The Options shall expire five (5) years from the initial grant date. Article content About Covalon Article content Covalon is a leading medical device company dedicated to improving patient outcomes through innovative and compassionate medical products and technologies. Our expertise spans advanced wound care, vascular access, and surgical consumables, with a strong focus on enhancing healing, reducing healthcare-associated infections (HAIs), and protecting skin integrity. Our solutions are designed for patients and made for care providers. The Company is listed on the TSX Venture Exchange (COV) and trades on the OTCQX Market (CVALF). To learn more about Covalon, visit our website at Article content . Article content Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Article content This news release may contain forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as 'seek', 'anticipate', 'plan', 'estimate', 'expect', 'intend', or variations of such words and phrases or state that certain actions, events, or results 'may', 'could', 'would', 'might', 'will' or 'will be taken', 'occur', or 'be achieved'. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts, but instead represent management's expectations, estimates, and projections regarding future events. Forward-looking statements involve risks and uncertainties, including, but not limited to, the factors described in greater detail in the 'Risks and Uncertainties' section of our management's discussion and analysis of financial condition and results of operations for the year ended September 30, 2024, which is available on the Company's profile at Article content Article content , any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company assumes no obligation to update or alter any forward-looking statements, whether as a result of new information, further events, or otherwise, except as required by law. Article content Article content Article content
